Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville
FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that it entered into a Pre-Paid Advance Agreement (the “Agreement”) with YA II PN, LTD (“Yorkville”), an affiliate of Yorkville Advisors Global, LP.
Related news for (CELU)
- Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
- 24/7 Market News Snapshot 14 October, 2025 – Celularity Inc. Class A Common Stock (NASDAQ:CELU)
- MoBot’s Stock Market Highlights – 07/15/25 06:00 AM
- Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
- Celularity Receives Nasdaq Notice Regarding Form 10-Q